Abstract
The transcription factor NF-κB has anti-apoptotic properties and may confer chemoresistance to cancer cells. Here, we describe human pancreatic carcinoma cell lines that differ in the responsiveness to the topoisomerase-2 inhibitors VP16 (20 μM) and doxorubicin (0.3 μM): Highly sensitive BxPC-3 and PT45-P1 cells, and Capan-1 and A818-4 cells that were almost resistant to both anti cancer drugs. VP16, but not doxorubicin, transiently induced NF-κB activity in all cell lines, whereas basal NF-κB binding was nearly undetectable in BxPc-3 and PT45-P1 cells, but rather high in Capan-1 and A818-4 cells, as demonstrated by gel-shift and luciferase assays. Treatment with various NF-κB inhibitors (Gliotoxin, MG132 and Sulfasalazine), or transfection with the IκBα super-repressor, strongly enhanced the apoptotic effects of VP16 or doxorubicin on resistant Capan-1 and 818-4 cells. Our results indicate that under certain conditions the resistance of pancreatic carcinoma cells to chemotherapy is due to their constitutive NF-κB activity rather than the transient induction of NF-κB by some anti-cancer drugs. Blockade of basal NF-κB activity by well established drugs efficiently reduces chemoresistance of pancreatic cancer cells and offers the potential for improved therapeutic strategies.
Similar content being viewed by others
Change history
18 April 2002
A Correction to this paper has been published: https://doi.org/10.1038/sj.onc.1205379
Abbreviations
- FITC:
-
fluorescein isothiocyanate
- IKK:
-
IκB kinase
- NF-κB:
-
nuclear factor κB
- PVDF:
-
polyvinylidene difluoride
References
Barkett M and Gilmore TD. . 1999 Oncogene 18: 6910–6925.
Das KC, Guo XL and White CW. . 1998 J. Biol. Chem. 273: 34639–34645.
Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C and Leutz A. . 1999 Oncogene 18: 3316–3323.
Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE and Giaccone G. . 1999 Clin. Cancer Res. 5: 2048–2058.
Egawa N, Maillet B, VanDamme B, De Greve J and Klöppel G. . 1996 Virchows Arch. 429: 59–68.
Estival A, Clerc P, Vaysse N, Tam JP and Clemente F. . 1992 Gastroenterology 103: 1851–1859.
Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR and Hickson ID. . 1991 Cancer Res. 51: 6592–6595.
Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB and Brenner DA. . 1998 Hepatology 27: 1285–1295.
Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T and Debatin KM. . 1998 Blood 91: 4624–4631.
Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmüller G, Scherer E, Maurer J, Maacke H and Deppert W. . 1993 Oncogene 8: 289–298.
Kingma PS and Osheroff N. . 1998 Biochim. Biophys. Acta 1400: 223–232.
Kothny-Wilkes G, Kulms D, Poppelmann B, Luger TA, Kubin M and Schwarz T. . 1998 J. Biol. Chem. 273: 29247–29253.
Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B and Scheidereit C. . 1999 Oncogene 18: 943–953.
Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D and Goldenberg GJ. . 1999 Leuk. Res. 23: 871–880.
Liu ZG, Hsu H, Goeddel DV and Karin M. . 1996 Cell 87: 565–576.
Long BH, Wang L, Lorico A, Wang RC, Brattain MG and Casazza AM. . 1991 Cancer Res. 51: 5275–5283.
Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H and Liu LF. . 1999 Biochemistry 38: 10793–10800.
Mazo A, Fujii Y, Shimotake J and Escribano MJ. . 1991 Pancreas 6: 37–45.
McDade TP, Perugini RA, Vittimberga Jr FJ, Carrigan RC and Callery MP. . 1999 J. Surg. Res. 83: 56–61.
Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL. . 1999 Genes Dev. 13: 2490–2501.
Pahl HL, Krauss B, Schulze-Osthoff K, Decker T, Traenckner EB, Vogt M, Myers C, Parks T, Warring P, Muhlbacher A, Czernilofsky AP and Baeuerle PA. . 1996 J. Exp. Med. 183: 1829–1840.
Salminen A, Tapiola T, Korhonen P and Suuronen T. . 1998 Brain Res. Mol. Brain Res. 30: 203–206.
Schäfer H, Diebel J, Arlt A, Trauzold A and Schmidt WE. . 1998 FEBS Lett. 436: 139–143.
Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK and Collins T. . 1999 Mol. Cell. Biol. 19: 6367–6378.
Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B and Kalthoff H. . 1998 Cancer Res. 58: 1741–1749.
Wahl C, Liptay S, Adler G and Schmid RM. . 1998 J. Clin. Invest. 101: 1163–1174.
Wang CY, Mayo MW and Baldwin Jr AS. . 1996 Science 274: 784–787.
Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ. . 1999a Clin. Cancer Res. 5: 119–127.
Wang CY, Guttridge DC, Mayo MW and Baldwin Jr AS. . 1999b Mol. Cell. Biol. 19: 5923–5929.
Widlak P, Gaynor RB and Garrard WT. . 1997 J. Biol. Chem. 272: 17654–17661.
Zong WX, Bash J and Gelinas C. . 1998 Cell Death Differ. 5: 963–972.
Acknowledgements
This work was supported by grants of the IZKF Kiel and the Hensel-Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arlt, A., Vorndamm, J., Breitenbroich, M. et al. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20, 859–868 (2001). https://doi.org/10.1038/sj.onc.1204168
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204168
- Springer Nature Limited
Keywords
This article is cited by
-
The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway
Journal of Experimental & Clinical Cancer Research (2017)
-
Inhibition of NUCKS Facilitates Corneal Recovery Following Alkali Burn
Scientific Reports (2017)
-
Effect of NF-κB inhibition on chemoresistance in biliary–pancreatic cancer
Surgery Today (2015)
-
c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells
Cell Death & Disease (2014)
-
Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure
Acta Pharmacologica Sinica (2014)